Quick Facts

• Primary Therapeutic Domain: Managing elevated blood pressure (hypertension).
• Secondary Uses: Support in the management of specific heart conditions, including chronic stable angina and heart failure.

Amace is a combination pharmacological agent used in the long-term management of high blood pressure, a condition also known as hypertension. Maintaining blood pressure within an acceptable range is a key component of a comprehensive cardiovascular health strategy.

This medication is also an established treatment option utilized to support individuals with chronic stable angina, a form of chest discomfort resulting from reduced blood flow to the heart muscle. Additionally, Amace may be prescribed as part of a regimen to manage symptoms associated with heart failure.

Consultation with a healthcare professional is necessary to determine the appropriate therapeutic role of Amace for any patient's specific health needs.

Regulatory References

1. NIH MedlinePlus guidance

This section summarizes the official eligibility profile for the medicine, derived from regulatory documents, which often contains the active ingredients amlodipine and benazepril.

Eligibility Scope

Category	Regulatory Status
Populations for whom use is contraindicated	Patients with a history of angioedema related to any previous treatment with an Angiotensin-Converting Enzyme (ACE) inhibitor, or those with known hypersensitivity to the active components. Use is also contraindicated in patients with diabetes receiving the drug aliskiren, and in combination with a neprilysin inhibitor (e.g., sacubitril).
Pregnancy and lactation eligibility	Contraindicated in the second and third trimesters of pregnancy due to risk of fetal injury and death. Treatment must be discontinued immediately upon detection of pregnancy. Use is generally not recommended during breastfeeding.
Age-related eligibility rules	Pediatric use is not established; safety and efficacy in children are not officially determined. Older adults may require careful dose adjustment due to potentially slower drug clearance.
Condition-specific eligibility limitations	Use requires special consideration in patients with severe renal impairment (creatinine clearance leq 30 mL/min) and severe hepatic impairment.

Interactions with other medicines and products

Official government regulatory documents for Amace (Amlodipine/Enalapril) establish specific constraints regarding co-administration with other medicines and products, focusing on the distinct profiles of its two components.

Prohibited and Restricted Combinations

Classification	Interacting Substance/Class	Regulatory Requirement
Contraindicated	Sacubitril/Valsartan (ARNI)	Prohibited combination; a 36-hour washout period is mandatory when switching to or from Enalapril due to the risk of angioedema.
Contraindicated	Aliskiren (Direct Renin Inhibitor)	Prohibited in patients with diabetes or renal impairment due to increased risks of hyperkalemia, hypotension, and renal dysfunction.
Restricted	Simvastatin (Statin)	The daily dose of Simvastatin must be limited to a maximum of 20 mg due to increased systemic exposure caused by the Amlodipine component.

Pharmacodynamic and Metabolic Interactions

Interactions involving the Enalapril component primarily concern its effects on the renin-angiotensin system and electrolytes:

• Potassium-Sparing Diuretics (e.g., Spironolactone, Triamterene) and Potassium Supplements: These substances carry an increased risk of hyperkalemia (elevated blood potassium levels) when combined with Enalapril.
• NSAIDs (Nonsteroidal Anti-Inflammatory Drugs): Co-administration may result in reduced blood pressure lowering and increased risk of renal function deterioration.
• Lithium: Enalapril may reduce the renal clearance of Lithium, leading to elevated serum Lithium levels.

Interactions involving the Amlodipine component are often related to metabolism:

• Strong/Moderate CYP3A4 Inhibitors (e.g., Clarithromycin, Itraconazole): These substances increase the plasma concentration of Amlodipine.
• Grapefruit Juice: Consumption is discouraged as it may increase the bioavailability and blood pressure lowering effect of Amlodipine.

These constraints define the official interaction profile, which requires adherence to specific separation times and dose limits for certain co-administered medicines.

Amace functions as a selective non-nitrogen-containing bisphosphonate, primarily targeting the enzyme farnesyl pyrophosphate synthase (FPPS) within the mevalonate pathway of osteoclasts. It is taken up by bone mineral where it accumulates and is then internalized by osteoclasts during the process of bone resorption.

Inside the osteoclast, Amace competitively inhibits the catalytic activity of FPPS. This enzyme is essential for synthesizing isoprenoid lipids, specifically farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP). The inhibition prevents the subsequent prenylation of small guanosine triphosphate (GTP)-binding signaling proteins, such as Ras, Rho, and Rac.

Non-prenylated GTPases cannot correctly localize to the cell membrane, disrupting crucial intracellular signaling cascades necessary for osteoclast function and cytoskeletal integrity. This molecular cascade ultimately leads to the programmed cell death (apoptosis) of the osteoclast, thereby modulating the rate of bone matrix degradation on a physiological level.

Amace, a fixed-dose combination containing Amlodipine and Enalapril, is used for the long-term management of chronic high blood pressure. The medicine is intended for oral administration as a tablet and is intended for a once daily frequency. The dose may be taken with or without food, ensuring flexibility in the daily regimen.

Dosing protocols direct that treatment typically begins with the lowest available combination strength (e.g., Amlodipine 2.5 mg / Enalapril 10 mg equivalent) and is then adjusted based on the patient’s blood pressure response. The standard usage protocol mandates a minimum interval of 7 to 14 days between any dosage adjustments to ensure the fixed combination’s full therapeutic effect is accurately evaluated before titration.

Population and Procedural Rules

Feature	Standard Instruction
Dose Initiation	Often started after failure to achieve blood pressure control with monotherapy.
Older Adults	Initiation at the lowest available component dose (e.g., Amlodipine 2.5 mg) may be required.
Hepatic Impairment	Treatment must be initiated at the lowest available dose with cautious, slow titration.
Missed Dose	If a dose is missed, take the next dose at the regularly scheduled time; do not take two doses at once.

These instructions define the standardized, procedural steps for using Amace, ensuring the use of a simple, once-daily oral schedule, governed by mandatory time intervals for safe and structured dose adjustment.

Research Evidence / Overview of Studies for Amace

Amace is a fixed-dose combination (FDC) formulation containing Amlodipine and Enalapril. The research base for this combination is built upon studies focused on its evaluation in patients with high blood pressure, and also draws on the long-established research for its two components in conditions where physiological strain or stress was monitored.

---

Evidence for Use in Managing Essential Hypertension

Research has explored the evaluation of the combination in lowering blood pressure, primarily through Randomized Controlled Trials (RCTs). Studies monitored blood pressure changes in adults, and the evidence base for evaluation in this population is built upon extensive research, though FDC-specific evidence is often short-term. Trials also examined the combination against single-agent treatments, and this approach was monitored in trials comparing it to single-agent treatment. The main outcomes monitored in these trials were changes in Systolic and Diastolic Blood Pressure (SBP/DBP).

---

Evidence for Specific Supportive Uses (Angina and Heart Failure)

Research has explored the use of the individual components of Amace in related conditions. The Amlodipine component was studied for chronic stable angina, where outcomes related to physical discomfort were monitored. Research has also examined the use of the Enalapril component in individuals where symptoms associated with heart failure were monitored, including the risk of heart failure hospitalization and long-term survival. For the FDC product itself, the clinical research is primarily focused on its use in patients with concurrent hypertension and heart failure.

---

Key Limitations and Areas of Research Uncertainty

Assessing the long-term impact is critical. The main evidence for long-term outcomes related to cardiovascular events is extrapolated from large trials of the two individual drug classes, rather than from dedicated, multi-year trials of the fixed-dose combination product itself. Follow-up durations were limited in some studies designed to show additive effects, and data for certain groups (e.g., specific comorbidities or pregnant populations) remain insufficient.

Key Studies & References

1. ACE Inhibitors - StatPearls - NCBI Bookshelf

Common questions about Amace (FAQ)

Q: Is Amace a brand-new medicine or has it been around for a while?

A: The components of Amace have a long history of use. Official records indicate that both active ingredients, Amlodipine and Enalapril, have been approved and utilized in clinical practice for the management of high blood pressure for several decades. The fixed-dose combination leverages these well-established medicines.

Q: Can taking Amace affect my weight?

A: According to official product information, weight changes are noted as a possible effect. Both weight gain and weight loss have been reported as side effects. Specifically, weight gain is sometimes associated with oedema (swelling), which is the documented swelling linked to the Amlodipine component.

Q: Is Amace considered to be an addictive medicine?

A: Amace is not classified as a controlled substance by major regulatory authorities. This means the medicine is not considered an addictive medication.

Q: Is Amace available as a generic medicine?

A: Official information confirms that the active ingredients in Amace—Amlodipine and Enalapril—are both widely available in generic form. This means the generic versions of the components are available on the market.

Q: Does Amace affect my immune system?

A: Regulatory documents indicate that the Enalapril component carries warnings related to rare blood disorders. These warnings include the potential for bone marrow depression, a condition that affects blood cell production, which is a factor noted for special consideration in regulatory documents.

Q: What kind of tests or monitoring are needed when taking Amace?

A: Because the medicine contains an ACE inhibitor (Enalapril), regulatory documents highlight the practice of periodic monitoring. Official regulatory documents indicate that monitoring kidney function and blood potassium levels is a recommended practice when the Enalapril component is used.

Q: Is Amace a controlled substance?

A: No, Amace is not classified as a controlled substance by regulatory authorities.

Q: Where can I find published research about Amace?

A: Official summaries of the clinical studies that led to the approval of Amace are included in the Clinical Studies section of the full regulatory prescribing information. This section typically contains an overview of the data and findings.

Q: Does Amace interact with alcohol?

A: Yes, regulatory documents indicate that alcohol may cause an additive effect with Amace. This can increase the blood pressure-lowering action, potentially leading to symptoms like dizziness or lightheadedness, especially when initiating treatment.

Q: Are there specific vitamins or herbal supplements that interact with Amace?

A: Official information indicates interactions with certain supplements. The Enalapril component carries a risk of high potassium when taken with potassium supplements. Additionally, multivitamins containing minerals may decrease the effects of the Amlodipine component.

Q: Is it true that Amace should not be taken with certain types of food?

A: The Amlodipine component has a documented interaction with grapefruit juice. The official product information advises against the consumption of grapefruit juice because it may increase the bioavailability of the drug, which is how much medication enters the bloodstream.

Q: Do I need to follow a special diet while using Amace?

A: While regulatory documents specifically mention avoiding grapefruit juice, general medical guidelines for high blood pressure management often include lifestyle changes. For the management of high blood pressure, general medical guidelines often recommend lifestyle changes, which may include a low-salt diet.

Q: How long does it usually take for Amace to start showing an effect?

A: The full blood pressure-lowering effect is typically achieved within 7 to 14 days after a dose adjustment. While the maximum effect of the Enalapril component may begin in a few hours, the Amlodipine component has a more gradual onset.

Q: Does the effect of Amace wear off quickly after I stop taking it?

A: The Amlodipine component has a long half-life of 30–50 hours, meaning the medication stays in the body for an extended period. Abrupt withdrawal of the Enalapril component is generally not associated with a rapid increase in blood pressure.

Q: How does Amace differ from similar medicines used for the same condition?

A: Amace is a fixed-dose combination that uses two different mechanisms (a Calcium Channel Blocker and an ACE Inhibitor) to lower blood pressure, which is often a clinically recognized strategy for patients needing more than one agent.

Q: Is Amace suitable for people with a history of heart issues?

A: The individual components are used to manage specific heart conditions, such as angina (Amlodipine) and heart failure (Enalapril). However, regulatory documents indicate that special consideration and monitoring may be necessary when this medicine is used by individuals with certain cardiac conditions, such as ischemic heart disease.

Q: Are there studies suggesting Amace could be used for other health issues?

A: Research has explored the individual components of Amace for uses beyond high blood pressure. These have included studies on certain types of angina and heart failure. The primary approved purpose of the combination is high blood pressure management.

Q: Why do some forums say Amace is only for the most severe cases?

A: Regulatory protocols indicate the fixed-dose combination is often initiated after a patient has failed to achieve blood pressure control with a single-agent (monotherapy) treatment. This indicates its intended use is for individuals who may benefit from a multi-pathway approach involving two different drug classes.

Q: Why is it described that Amace works differently than older treatments?

A: Amace uses a dual mechanism of action, combining two major drug classes (CCB and ACE Inhibitor). This approach simultaneously targets two separate biological pathways to lower blood pressure, a strategy that is often utilized to achieve blood pressure goals when single-agent treatments have not been sufficient.

Q: I heard Amace can cause stomach upset; is that a common side effect?

A: Gastrointestinal symptoms are documented side effects of the Enalapril component. These can include nausea and abdominal pain. Nausea is reported as a very common (10% or more) side effect.

Q: Does Amace have any known long-term side effects?

A: Rare, but serious, effects related to the Enalapril component are documented in regulatory warnings. These may include liver problems or kidney function deterioration (acute renal failure), which are factors noted for special consideration and ongoing evaluation in regulatory documents.

Q: Can Amace cause a rash or other skin reaction?

A: Yes, official documentation lists skin reactions. A skin rash is listed as a less common side effect of the Enalapril component, and a mild allergic reaction, including rash, is also documented for Amlodipine.

Official Storage and Disposal Requirements for Amace

Regulatory labeling dictates specific conditions for storing and disposing of Amace to maintain product integrity and ensure safety. This information is based strictly on governmental health authority documents.

Storage Component	Official Requirement
Temperature	Store at controlled room temperature, typically 20 C to 25 C.
Protection	Protect from moisture and excessive humidity; keep the container tightly closed and in its original package.
Prohibited Handling	Do not freeze or refrigerate Amace (unless otherwise specified on the label).
Child Safety	Keep Amace out of the reach and sight of children.

For stability, Amace must be used before the expiration date printed on the container. For disposal, unused or expired Amace must not be placed in household trash or flushed down the drain. Return the medicine to an approved pharmaceutical waste collection or drug take-back program as required by local regulations.